FDA Office of Regulatory Affairs Makeover Blends Domestic, International Work
This article was originally published in The Tan Sheet
Executive Summary
The reorganized ORA has eight new offices to better handle new legislative authorities and globalization of its regulated products; FDA expects to increase partnerships with other government officials and foreign entities.
You may also be interested in...
FDA Drug Shortage Staff Gets Higher Profile As New Reporting Requirements Begin
The 11-member staff CDER devotes to drug shortages is moving to the Office of the Center Director and will report to Deputy Director for Regulatory Programs Doug Throckmorton.
Generic Drugs Gain Status Boost Within CDER
More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.
ORA Lab Closings Cancelled But Reorganization Not Off The Table – Staffers
FDA's head of regulatory affairs' Aug. 17 message to staff about cancelling plans to close seven field labs did not mark the end of the agency's ORA reorganization work, staff members say